GlassScriptPhysician profile
Thomas G Plavac
NPI 1649272782
$9,419.34
in general payments reported to CMS, 2019-2025
35 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,632 · 2020: $782 · 2021: $1,067 · 2022: $2,319 · 2023: $996 · 2024: $1,350 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,199 · Travel and Lodging: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,198.91 |
| Travel and Lodging | $420.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,458.04 | 2019-2025 | |
| Medtronic, INC. | $1,373.41 | 2021-2025 | Symplicity G3, Onyx Frontier, Micra |
| Penumbra, INC. | $1,153.76 | 2022-2025 | Indigo System |
| Abiomed | $922.33 | 2019-2025 | Impella |
| Janssen Pharmaceuticals, INC | $723.52 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $527.97 | 2019-2024 | Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $522.63 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $495.89 | 2021-2025 | Verquvo |
| Amgen INC. | $397.09 | 2019-2023 | Repatha |
| Pfizer INC. | $323.03 | 2019-2025 | |
| Inari Medical, INC. | $309.02 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $169.17 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $130.46 | 2019-2020 | |
| Esperion Therapeutics, INC. | $121.26 | 2021-2025 | Nexletol |
| Medtronic Vascular, INC. | $83.53 | 2019 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Plavac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.